

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9877)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF THE FIRST FEE-FOR-SERVICE
COMPASSIONATE USE TREATMENT WITH LUX-VALVE PLUS IN
THE ASIA-PACIFIC REGION

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and new product development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company and LifeTech Scientific Corporation (stock code: 1302) have recently collaborated to achieve the first fee-for-service compassionate use treatment with LuX-Valve Plus in the Asia-Pacific region, the Company’s transjugular tricuspid valve replacement product, which was successfully completed at the Hong Kong Asia Heart Centre (HKAHC). “Compassionate use” is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biological product, or medical device) to obtain treatment outside of clinical trials when no comparable or satisfactory alternative treatment options are available. On this basis, the Company will further accelerate the commercialization of LuX-Valve Plus on a global scale.

Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize LuX-Valve Plus successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jenscare Scientific Co., Ltd.
Mr. LV Shiwen
Chairman and Executive Director

Hong Kong, August 7, 2023

As at the date of this announcement, the executive Directors are Mr. LV Shiwen and Mr. PAN Fei; the non-executive Directors are Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.